Technological advances have made it possible to study a patient from multiple angles with
high-dimensional, high-throughput multiscale biomedical data. In oncology, massive …

The MYC transcription factor, encoded by the c‐MYC proto‐oncogene, is activated by
growth‐promoting signals, and is a key regulator of biosynthetic and metabolic pathways …

Data on long-term outcomes and biological drivers associated with depth of remission after
BCL2 inhibition by venetoclax in the treatment of chronic lymphocytic leukemia (CLL) are …

Targeting metabolic vulnerability of tumor cells is a promising anticancer strategy. However,
the therapeutic efficacy of existing metabolism‐regulating agents is often compromised due …

Despite available targeted treatments for the disease, drug-resistant chronic lymphocytic
leukemia (CLL) poses a clinical challenge. The objective of this study is to examine whether …

Chronic lymphocytic leukemia (CLL) is a B-cell neoplasm with a heterogeneous clinical
behavior. In 5–10% of patients the disease transforms into a diffuse large-B cell lymphoma …

Reactive oxygen species (ROS), previously considered toxic by-products of aerobic
metabolism, are increasingly recognized as regulators of cellular signaling. Keeping ROS …

The tumour microenvironment and genetic alterations collectively influence drug efficacy in
cancer, but current evidence is limited and systematic analyses are lacking. Using chronic …

Genetic testing has been applied for decades in clinical routine diagnostics of hematological
malignancies to improve disease (sub) classification, prognostication, patient management …

Richter's transformation (RT) is a progression of chronic lymphocytic leukemia (CLL) to
aggressive lymphoma. MGA (Max gene associated), a functional MYC suppressor, is …